Rezolute, Inc. (NASDAQ:RZLT) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Rezolute, Inc. (NASDAQ:RZLT) has received a consensus rating of “Moderate Buy” from the twelve research firms that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $9.3750.

Several analysts recently weighed in on RZLT shares. Zacks Research downgraded Rezolute from a “hold” rating to a “strong sell” rating in a research report on Thursday, July 16th. Wall Street Zen downgraded Rezolute from a “hold” rating to a “sell” rating in a research note on Tuesday, June 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Rezolute in a report on Friday, July 17th. Maxim Group raised their price target on shares of Rezolute from $10.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, June 2nd. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Rezolute in a report on Thursday.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. BNP Paribas Financial Markets acquired a new stake in shares of Rezolute during the 2nd quarter valued at $25,000. ExodusPoint Capital Management LP bought a new stake in Rezolute during the 4th quarter worth $25,000. HB Wealth Management LLC acquired a new position in Rezolute in the 4th quarter worth about $26,000. Fifth Third Wealth Advisors LLC acquired a new position in Rezolute in the 4th quarter worth about $29,000. Finally, Hsbc Holdings PLC bought a new position in Rezolute in the fourth quarter valued at about $29,000. 82.97% of the stock is currently owned by institutional investors.

Rezolute Price Performance

Shares of NASDAQ:RZLT opened at $4.72 on Friday. The company has a market capitalization of $454.49 million, a P/E ratio of -5.76 and a beta of 0.54. Rezolute has a 1 year low of $1.07 and a 1 year high of $11.46. The business’s 50 day simple moving average is $4.56 and its 200 day simple moving average is $3.66.

Rezolute (NASDAQ:RZLT) last issued its earnings results on Tuesday, May 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.01. On average, sell-side analysts anticipate that Rezolute will post -0.69 EPS for the current fiscal year.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.